|2.22|| 0.00 / 0.00%|
Soligenix, Inc. is a clinical stage biopharmaceutical company, which engages in developing products to treat serious gastrointestinal diseases. It operates through the BioTherapeutics and Vaccines or BioDefense segments. The BioTherapeutics segment involves in the development of photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma. The Vaccines or BioDefense segment includes active development programs for RiVax, ricin toxin vaccine candidate, OrbeShield, GI acute radiation syndrome therapeutic candidate, and SGX943, melioidosis therapeutic candidate. The company was founded in 1987 and is headquartered Princeton, NJ.
|Christopher J. Schaber||Chairman, President & Chief Executive Officer|
|Karen R. Krumeich||Chief Financial Officer, Secretary & Senior VP|
|Oreola Donini||Chief Scientific Officer & Senior Vice President|
|Richard C. Straube||Chief Medical Officer & Senior Vice President|
|Adam T. Rumage||VP-Regulatory Affairs & Project Management|